

Serum vitamin D levels and the severity and clinical course of COVID-19

Mohamed Elnady,¹ Ahmed Abdel Hafeez,¹ Hebatallah Assal,¹ Eman Zaid,² Gihan Abo Elwafa¹

¹Department of Chest Diseases, Faculty of Medicine, Cairo University; ²Giza Chest Hospital, Egypt

Abstract

Low vitamin D levels are associated with different pulmonary diseases, such as chronic obstructive pulmonary disease, bronchial asthma, and obstructive sleep apnea. In this study, we aimed to assess the relation between vitamin D levels and COVID-19

severity. Positive COVID-19 patients were subjected to clinical examination, computed tomography of the chest, and laboratory investigations. Serum vitamin D level was measured and correlated with the severity and the clinical course of the disease. The study included 72 patients, classified into four groups according to the severity of the disease. There was a statistically significant difference between the four groups regarding age, lymphocyte count, serum vitamin D, C-reactive protein, and lactate dehydrogenase levels. Serum vitamin D levels can be correlated with COVID-19 severity and clinical course.

Correspondence: Gihan Abo Elwafa, Department of Chest Diseases, Faculty of Medicine, Cairo University, Kasr Alainy, Manial, Cairo, Egypt.

Tel.: 0223641088.

E-mail: gigi2012chest@gmail.com

Key words: COVID-19, vitamin D, C-reactive protein.

Contributions: ME, AAH, HA, conceptualization and design, writing - review and editing; EZ, GAE, acquisition and interpretation, writing - original draft preparation. All authors approved the final manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: the study was approved by the research ethics committee of the Faculty of Medicine, Cairo University (No: MD-236-2022).

Informed consent: written informed consent was obtained from each patient.

Patient consent for publication: not applicable.

Availability of data and materials: data and materials are available from the corresponding author upon request.

Funding: none.

Received: 7 March 2024.

Accepted: 26 August 2024.

Early view: 26 September 2024.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

©Copyright: the Author(s), 2024

Licensee PAGEPress, Italy

Monaldi Archives for Chest Disease 2025; 95:2978

doi: 10.4081/monaldi.2024.2978

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Introduction

Disease severity in COVID-19 is assessed by the occurrence of pneumonia, acute respiratory distress syndrome, vascular thrombosis, myocarditis, and cytokine storm, with inflammation being the main pathogenic mechanism [1]. Vitamin D deficiency is associated with an increase in inflammatory cytokines, and vitamin D supplementation can increase the level of T regulatory lymphocytes (which protect against uncontrolled inflammation), which were found to be extremely low in severe cases of COVID-19 [2]. Vitamin D can protect against respiratory tract infections as it enhances T-lymphocytes chemotaxis, and induces apoptosis and autophagy of infected epithelial cells, facilitating the removal of infecting organisms [3]. It possesses antiviral activity as it can inhibit replication of the virus by stimulating monocytes and macrophages to release cathelicidin and defensin proteins [4]. The aim of our study was to assess the relation between serum level of vitamin D, severity, and clinical course of COVID-19 infection.

Materials and Methods

This prospective study was conducted from November 2022 to March 2023, and it was approved by the research ethics committee of the Faculty of Medicine, Cairo University (No: MD-236-2022). Written informed consent was obtained from each patient.

The study included 72 patients diagnosed with COVID-19 infection, classified according to the disease severity grades of the World Health Organization definition into 4 groups [5]: group 1 – asymptomatic patients; group 2 – patients with mild disease, group 3 – patients with moderate disease; group 4 – patients with severe disease.

Disease severity grades of the World Health Organization

Mild disease: symptomatic patients meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia.

Moderate disease: adult with clinical signs of pneumonia (fever, cough, dyspnea, fast breathing) but no signs of severe

pneumonia, including saturation of peripheral oxygen (SpO₂) $\geq 90\%$ on room air. The diagnosis can be made on clinical grounds; chest imaging [radiograph, computed tomography (CT) scan, ultrasound] may assist in diagnosis and identify or exclude pulmonary complications.

Severe disease: adult with clinical signs of pneumonia (fever, cough, dyspnea) plus one of the following: respiratory rate >30 breaths/min, severe respiratory distress, or SpO₂ $<90\%$ on room air. The diagnosis can be made on clinical grounds; chest imaging (radiograph, CT scan, ultrasound) may assist in diagnosis and identify or exclude pulmonary complications.

Inclusion and exclusion criteria

Adult patients with confirmed COVID-19 infection were included; confirmed cases were defined as a positive result of a real-time reverse transcriptase polymerase chain reaction assay of nasopharyngeal swab. Exclusion criteria included patients with liver disease, chronic renal disease, parathyroid disease, and malabsorption.

Methodology

History taking was performed with particular attention to age, comorbidities, and symptoms of COVID-19, physical examination, including vital signs (temperature, heart rate, respiratory rate), and oxygen saturation. A CT of the chest was done. Laboratory investigations included complete blood count and inflammatory markers, such as C-reactive protein (CRP) and serum lactate dehydrogenase (LDH). Determination of serum vitamin D levels was conducted by an enzyme-linked immunosorbent assay kit (Biovation Inc., Beijing, China) according to the manufacturer's instructions.

Statistical methods

The data was statistically analyzed *via* the Minitab program 17.1.0.0 for Windows (Minitab Inc., State College, PA, USA). Continuous data were presented as mean and standard deviation, and categorical data as number and percentage (%). The normality of data was examined using the Shapiro-Wilk test. Comparison between means of more than two groups was performed by one-way analysis of variance test with Turkey methods for intergroup comparison, independent *t*-test, and by Kruskal-Wallis test for non-parametric data, while Chi-square test was used for comparing between groups of categorical data. Pearson correlation coefficient was used for linear relationship evaluation, the sign before “*r*” denoting the direction of the relation. All tests were two-sided, and $p \leq 0.05$ was considered significant.

Results

Table 1 shows the demographics of the study population. The mean age of asymptomatic and mild COVID-19 patients was significantly lower than those with moderate and severe disease ($p < 0.001$), and the number of female patients was significantly higher in the mild disease group in relation to other groups ($p = 0.02$). Chronic pulmonary diseases included chronic obstructive pulmonary disease, bronchial asthma, and fibrotic hypersensitivity pneumonitis. Neurological disorders included Parkinsonism and old stroke and were reported frequently in severe cases ($p < 0.001$).

Table 2 summarizes the laboratory investigation results of the study population. Total leucocyte count, CRP, and LDH were significantly elevated in moderate and severe COVID-19 disease, while lymphocytes % and hemoglobin were significantly decreased.

Table 1. Demographics of the study population.

	Group 1		Group 2		Group 3		Group 4		p
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
Age	41.67	12.18	46.67	12.05	65.67	14.74	67.78	14.24	<0.001
	N	%	N	%	N	%	N	%	
Sex									
Female	8	44.44	16	88.89	9	50	9	50	0.02
Male	10	55.56	2	11.11	9	50	9	50	
Comorbidities									
Diabetes mellitus	2	11.11	5	27.78	8	44.44	8	44.44	0.07
Systemic hypertension	4	22.22	9	50	11	61.11	9	50	0.09
Chronic pulmonary diseases	3	16.67	2	11.11	5	27.78	8	44.44	0.11
Neurological disorders	0	0	1	5.56	1	5.56	6	33.33	0.006

SD, standard deviation.

Table 2. Laboratory investigation results in the study groups.

	Group 1		Group 2		Group 3		Group 4		p
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
Total leucocyte count	8.29	3.24	7.26	3.04	7.74	3.39	14.66	9.18	0.001
Lymphocytes (%)	37.82	14.09	38.91	12.18	36.74	18.92	14.89	17.04	0.001
Hemoglobin	12.79	1.02	12.36	1.98	11.50	1.67	11.24	2.16	0.03
Platelets count	264.2	18.2	293.2	19.7	244	20.7	282.4	28.3	0.38
CRP	4.72	0.97	4.44	0.92	27.89	5.72	49.00	9.56	<0.001
LDH	242.1	44.3	251.4	56.5	425.5	102.2	441.7	147.4	<0.001

SD, standard deviation; CRP, C-reactive protein; LDH, serum lactate dehydrogenase.

Table 3 showed the serum level of vitamin D among the studied groups, and Table 4 showed the serum level of vitamin D in relation to the clinical course of patients.

Figures 1 and 2 show the correlation between serum vitamin D level and CRP, LDH, total leucocyte count, and lymphocytes %. There was a significant negative linear correlation between CRP, LDH, total leucocyte count, and the level of vitamin D in serum. The correlation between serum vitamin D level and lymphocytes (%) was significantly positive.

Discussion

Vitamin D has an immune-regulatory function. Through its receptors (located on multiple immune cells such as dendritic cells, monocytes, and activated lymphocytes), it can affect activation and proliferation of immune cells, production of antibodies and cytokines [6]. There is conflicting data about the relationship

between vitamin D deficiency and the increased risk of COVID-19, and the severity of the disease [7].

In this study, the severity of the disease increased with increasing age. These results were in line with those of Jain *et al.* [8], Vasheghani *et al.* [9], Kalichuran *et al.* [10], and Yosef *et al.* [11]. While Campi *et al.* did not observe any difference in the age between mild and severely symptomatic COVID-19 cases [12].

As is known in viral infections, elder patients have the greatest risk of severe disease and death. This can be attributed to many reasons. First, immunosenescence, where decreased production of T and B cells, impairment of innate immunity, and uncoordinated adaptive immune response occur. This results in ineffective viral clearance, and deranged immune response, and a cytokine storm [13]. Secondly, inflammaging (chronic subclinical systemic inflammation that occurs in old age) predisposes to unfavorable outcomes in old COVID-19 patients [14]. Thirdly, comorbidities associated with old age increase the risk for severe COVID-19 [15].

Table 3. Serum vitamin D levels in the study groups.

Serum vitamin D level	Group 1		Group 2		Group 3		Group 4		p
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
	17.18	4.92	14.165	2.074	12.923	2.467	10.083	2.082	<0.001

SD, standard deviation.

Table 4. Serum vitamin D level and course of the disease.

Outcome	N	%	Serum vitamin D		p
			Mean	SD	
Deteriorated	12	16.67	9.633	2.192	<0.0001
Improved	42	58.33	13.178	2.408	

SD, standard deviation.




Figure 1. Correlation between serum vitamin D level with total leucocyte count and lymphocytes %.




Figure 2. Correlation between serum vitamin D level and inflammatory markers. CRP, C-reactive protein; LDH, serum lactate dehydrogenase.

In our study, serum level of vitamin D was significantly associated with the severity ($p < 0.001$) and with the clinical course of the disease ($p < 0.0001$). This agreed with previous studies [8-12,16-20], while Abdel Ati and Shahin and AlKhafaji *et al.* did not find any association between serum level of vitamin D and severity and outcome of COVID-19 [21,22].

Several explanations were proposed to demonstrate the relation between deficiency of vitamin D and COVID-19 risk and outcomes. Vitamin D enhances cellular immunity and can attenuate the levels of pro-inflammatory cytokines, such as tumor necrosis factor- α and interferon- γ (produced during the cytokine storm), while increasing the levels of anti-inflammatory cytokines [23]. It manipulates adaptive immune response by preventing T-helper 1 response, increasing production of T-helper 2 cytokines, and inducing T-regulatory cells [24]. It induces cathelicidin, interleukin-37, and defensins (antimicrobial peptides) and decreases viral replication [25]. It augments the expression of some antioxidant genes, such as the glutathione reductase gene [23]. Also, some studies have reported that vitamin D metabolites can have anticoagulant effects by altering the thrombomodulin and tissue factor expression in monocytes [26]. Absence of the previously mentioned roles of vitamin D may lead to the severe form of the disease.

This study revealed a significant negative correlation between serum vitamin D level, CRP, LDH, and total leucocyte count, while the relationship with lymphocytes % was significantly positive.

Similar results were reported by Yosef *et al.* and Renieris *et al.* [11,20]. While Qiu *et al.* found a non-significant link between serum vitamin D, lymphocyte, and LDH [19].

In this study, hemoglobin was found to be decreased in severe disease, which was in line with Wang *et al.* [27], and can be explained by altered erythropoiesis due to the effect of systemic inflammation, which is the main pathogenetic mechanism in COVID-19 [28].

In severe cases, leukocytosis with lymphopenia was observed, which was in line with the findings of Chen *et al.* and Yamadaa *et al.* [29,30]. Leucocytosis can be due to bacterial superinfection [31], and lymphopenia may be related to atrophy of lymphatic tissue,

direct lymphocyte invasion, or lymphocyte apoptosis due to inflammation and cytokine release [32].

Conclusions

Given the above-mentioned results and findings of multiple studies that assessed the effect of vitamin D supplementation on the risk of infection, severity, and outcomes of COVID-19, vitamin D supplementation may be an easy and inexpensive approach for decreasing the consequences of COVID-19.

References

- Weir E, Thenappan T, Bhargava M, Chen Y. Does vitamin D deficiency increase the severity of COVID-19? Clin Med 2020;20:e107-8.
- Fisher SA, Rahimzadeh M, Brierley C, et al. The role of vitamin D in increasing circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: a systematic review. PloS One 2019;14:e0222313.
- Kaya M, Pamukçu E, Yakar B. The role of vitamin D deficiency on COVID-19: a systematic review and meta-analysis of observational studies. Epidemiol Health 2021;43:e2021074.
- White JH. Vitamin D metabolism and signaling in the immune system. Rev Endocr Metab Disord 2012;13:21-9.
- World Health Organization. Clinical management of COVID-19: living guideline. Available from: <https://iris.who.int/bitstream/handle/10665/357004/WHO-2019-nCoV-Clinical-2022.1-eng.pdf?sequence=1>.
- Bui L, Zhu Z, Hawkins S, et al. Vitamin D regulation of the immune system and its implications for COVID-19: a mini review. SAGE Open Med 2021;9:20503121211014073.
- Wang Z, Joshi A, Leopold K, et al. Association of vitamin D deficiency with COVID-19 infection severity: Systematic review and meta-analysis. Clin Endocrinol 2022;96:281-7.

8. Jain A, Chaurasia R, Sengar N, et al. Analysis of vitamin D level among asymptomatic and critically-ill COVID-19 patients and its correlation with inflammatory markers. *Sci Rep* 2020;10:20191.
9. Vasheghani M, Jannati N, Baghaei P, et al. The relationship between serum 25-hydroxyvitamin D levels and the severity of COVID-19 disease and its mortality. *Scie Rep* 2021;11:17594.
10. Kalichuran S, van Blydenstein S, Venter M, Omar S. Vitamin D status and COVID-19 severity. *S Afr J Infect Dis* 2022;37:359.
11. Yosef T, Saleh S, Ali S, Elmetwally A. Vitamin D assessment in patients with COVID-19 virus and correlation with severity. *Egypt J Intern Med* 2022;34:52.
12. Campi I, Gennari L, Merlotti D, et al. Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy. *BMC Infectious Diseases* 2021;21:566.
13. Lord J, Veenith T, Sullivan J, et al. Accelerated immune ageing is associated with COVID-19 disease severity. *Immun Ageing* 2024;21:6.
14. Kang SJ, Jung SI. Age-related morbidity and mortality among patients with COVID-19. *Infect Chemother* 2020;52:154-64.
15. Starke K, Reissig D, Petereit-Haack G, et al. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with metaanalysis. *BMJ Glob Health* 2021;6:e006434.
16. Demir M, Demir F, Aygun H. Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease. *J Med Virol* 2021;93:2992-9.
17. Davoudi A, Najafi N, Aarabi M, et al. Lack of association between vitamin D insufficiency and clinical outcomes of patients with COVID-19 infection. *BMC Infect Dis* 2021;21:450.
18. Nielsen N, Junker T, Boelt S, et al. Vitamin D status and severity of COVID-19. *Sci Rep* 2022;12:19823.
19. Qiu Y, Bao W, Tian X, et al. Vitamin D status in hospitalized COVID-19 patients is associated with disease severity and IL-5 production. *Virol J* 2023;20:212.
20. Renieris G, Foutadakis S, Andriopoulou T, et al. Association of vitamin D with severity and outcome of COVID-19: clinical and experimental evidence. *J Innate Immun* 2024;16:1-11.
21. Abdel Ati M, Shahin M. Assessment of serum Vitamin D level in patients with COVID-19 infection. *Med J Cairo Univ* 2021;89:2247-51.
22. AlKhafaji D, Al Argan R, Albaker W, et al. The impact of vitamin D level on the severity and outcome of hospitalized patients with COVID-19 disease. *Int J Gen Med* 2022;15:343-52.
23. Kazemi A, Mohammadi V, Aghababae S, et al. Association of vitamin D status with SARS-CoV-2 infection or COVID-19 severity: a systematic review and meta-analysis. *Adv Nutr* 2021;12:1636-58.
24. Cantorna MT, Snyder L, Lin Y-D, et al. Vitamin D and 1,25 (OH) 2D regulation of T cells. *Nutrients* 2015;7:3011-21.
25. Barlow PG, Svoboda P, Mackellar A, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. *PLoS One* 2011;6:e25333.
26. Ruth Wu-Wong J. Are vitamin D receptor activators useful for the treatment of thrombosis? *Curr Opin Investig Drugs* 2009;10:919-27.
27. Wang C, Deng R, Gou L, et al. Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters. *Ann Transl Med* 2020;8:593.
28. Bergamaschi G, de Andreis F, Aronico N, et al. Anemia in patients with COVID-19: pathogenesis and clinical significance. *Clin Exp Med* 2021;21:239-46.
29. Chen R, Sang L, Jiang M, et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. *J Allergy Clin Immunol* 2020;146:89-100.
30. Yamadaa T, Wakabayashib M, Yamajic T, et al. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): a systematic review and meta-analysis. *Clin Chim Acta* 2020;509:235-43.
31. Sharma Y, Gawalkar A, Batta A, et al. Novel markers of COVID-19 mortality - a comparative study with patients of acute coronary syndrome. *J Family Med Prim Care* 2023;12:962-6.
32. Huang G, Kovalic A, Graber C. Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity. *Emerg Infect Dis* 2020;26:1839-41.